Oxford Biomedica Solutions Revenue and Competitors
Estimated Revenue & Valuation
- Oxford Biomedica Solutions's estimated annual revenue is currently $29.3M per year.
- Oxford Biomedica Solutions's estimated revenue per employee is $201,000
Employee Data
- Oxford Biomedica Solutions has 146 Employees.
- Oxford Biomedica Solutions grew their employee count by 10% last year.
Oxford Biomedica Solutions's People
Name | Title | Email/Phone |
---|
Oxford Biomedica Solutions Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $413.3M | 340 | 0% | $634M | N/A |
#2 | $57.9M | 288 | 0% | N/A | N/A |
#3 | $2M | 10 | -17% | N/A | N/A |
#4 | $33.6M | 167 | 20% | N/A | N/A |
#5 | $15.5M | 77 | 126% | N/A | N/A |
#6 | $25.1M | 125 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.1M | 50 | -2% | N/A | N/A |
#9 | $1.8M | 385 | -4% | $538M | N/A |
#10 | $46.6M | 232 | -7% | N/A | N/A |
What Is Oxford Biomedica Solutions?
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.
keywords:N/AN/A
Total Funding
146
Number of Employees
$29.3M
Revenue (est)
10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $33.7M | 146 | 11% | N/A |
#2 | $34.2M | 148 | 3% | N/A |
#3 | $66.3M | 150 | -7% | N/A |
#4 | $29.3M | 152 | 20% | N/A |
#5 | $24.7M | 155 | 35% | N/A |